CellVec
Singapore, Singapore· Est.
CellVec builds AI‑enhanced cell‑therapy platforms to deliver scalable oncology and rare‑disease treatments.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
CellVec builds AI‑enhanced cell‑therapy platforms to deliver scalable oncology and rare‑disease treatments.
Technology Platform
Proprietary CellVec Vector Suite combining engineered viral (AAV, lentiviral) and non‑viral delivery systems with AI‑driven design to enable rapid generation of CAR‑T, CAR‑NK, and gene‑edited cell therapies.
Opportunities
AI‑enhanced vector design and scalable manufacturing could position CellVec as a low‑cost provider of next‑generation cell therapies for oncology and rare diseases.
Risk Factors
Technical challenges in vector scale‑up, regulatory uncertainty for novel delivery platforms, and intense competition from established cell‑therapy developers.
Competitive Landscape
CellVec differentiates through its integrated AI‑vector platform, but competes with large pharma and well‑funded biotech firms advancing parallel CAR‑T and gene‑editing programs.